SAT-661 Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists

ENDO 2025 Abstract

The paper

Al Ashi S, Shah R, Iftikhar N et al.

ENDO 2025 Abstract · 22 Oct 2025 · CC BY-NC-ND

Presented at ENDO 2025

doi.org/10.1210/jendso/bvaf149.097